Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Harmony Biosciences logo — A fresh approach to helping patients thrive.

Harmony Biosciences

A fresh approach to helping patients thrive.

Founded 2017 United States United States 273 employees Post-IPO Debt Total: $1.44B Biopharma, Biotechnology +1

General Information

Company Name Harmony Biosciences
Founded Year 2017
Location United States United States
Founders / Decision Makers
Team member
Employees 273
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Harmony Biosciences. To contact Harmony Biosciences, visit harmonybiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Harmony Biosciences compare?

A PDF of Harmony Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Harmony Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Harmony Biosciences

Harmony Biosciences is a biopharma and biotechnology startup, founded in 2017 and headquartered in the United States. The company's slogan, "Patients are at the heart of everything we do," reflects its primary focus on developing and delivering treatments for rare neurological diseases. The organization's ethos revolves around the belief that the convergence of empathy and innovation can significantly enhance the lives of individuals afflicted with neurological disorders. Harmony Biosciences boasts a diverse team of experts representing various disciplines and experiences, all driven by the firm conviction that groundbreaking science can translate into tangible therapeutic possibilities. The company's core mission is to seamlessly transition novel therapies from the clinic to the medicine cabinet, while concurrently offering support to patients, providers, and the communities in which they operate. The company recently secured a significant $185.00M Post-IPO Debt investment on 27 July 2023, highlighting external confidence in its endeavors. As a private investor, recognizing Harmony Biosciences' commitment to addressing unmet medical needs in the realm of neurological diseases could unearth a promising investment opportunity. Moreover, tracking the company's progress and adherence to its stated community guidelines could provide valuable insights into its prospective growth trajectory. In conclusion, Harmony Biosciences' steadfast dedication to fostering innovation in neurological disease treatment, coupled with its recent substantial investment, positions it as a compelling prospect for potential venture capital consideration. For more information, please visit their website at Harmony Biosciences. For additional updates, follow them on Twitter at @Harmonybio.

Business keywords: Neurological diseases, Rare diseases, Therapeutic treatments, Innovation, Empathy, Clinical research, Medical science, Patient support, Community engagement, Healthcare innovation

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $185.00M -
27 Jul 2023
Post IPO Equity $200.00M -
01 Nov 2021
Post IPO Equity $30.00M 1
Blackstone Life Sciences
10 Aug 2021
Post IPO Debt $300.00M 1
Blackstone Group
Blackstone Group
10 Aug 2021
Debt Financing $200.00M 1
OrbiMed
OrbiMed
27 Jan 2020
Series C $50.00M 1
HBM Healthcare Investments
HBM Healthcare Investments
26 Aug 2019
Debt Financing $200.00M 1
CRG
CRG
13 Mar 2019
Venture Round $270.00M 7
Novo Holdings HBM Healthcare Investments Valor Equity Partners
Novo Holdings, HBM Healthcare Investments +5
06 Oct 2017

Harmony Biosciences Alternatives & Competitors

View All Alternatives
Harmony Biosciences vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care
Harmony Biosciences vs
Dualyx
Dualyx Belgium

Discovery and development of highly innovative biologicals for the treatment of autoimmune and rare...

Series A
6 employees
Biotechnology, Health Care
Harmony Biosciences vs
AveXis
AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting live...

Grant
Biotechnology, Health Care
Also compare with: Harmony Biosciences vs Astria Therapeutics, Inc. Astria Therapeutics, Inc. Harmony Biosciences vs Blueprint Genetics Blueprint Genetics View all alternatives

FAQ About Harmony Biosciences

A fresh approach to helping patients thrive.
Harmony Biosciences was founded in 2017.
Harmony Biosciences is headquartered in United States.
Harmony Biosciences operates in Biopharma, Biotechnology and Health Care. Its work centres on Neurological diseases, Rare diseases, Therapeutic treatments and Innovation.
Harmony Biosciences has approximately 273 employees.
Harmony Biosciences has completed 8 funding rounds, raising a total of $1.44B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Harmony Biosciences include Aceragen, Dualyx, AveXis, Axovia Therapeutics, EveryLife Foundation for Rare Diseases. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Harmony Biosciences and Aceragen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Harmony Biosciences, https://bouncewatch.com/company/harmony-biosciences, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout